People with early Alzheimer’s disease who stayed on lecanemab for five years declined more slowly than people with the disease who were never treated, the drug’s makers said on November 17th, 2026. Eisai and Biogen, the two companies that sell lecanemab, presented the figures at the Clinical Trials on Alzheimer’s Disease conference in Boston (the companies’ release). The untreated people were not in the trial. They come from two long-running studies that follow how the disease progresses, and that is the catch.
What was compared
Lecanemab is an antibody that clears amyloid, a protein that builds up in clumps in the brain in Alzheimer’s disease. Its main trial, Clarity AD, gave 1,795 people either the drug or a dummy infusion for 18 months. After that, 95 per cent of those who finished chose to carry on with the drug, and from then on nobody was on a dummy. To judge years three to five, the companies compared the 351 people who had five years of treatment with records from the Alzheimer’s Disease Neuroimaging Initiative, a United States study that has followed people with and without the disease since 2005, and from Sweden’s BioFINDER study (the companies’ release).
The figures
The companies measured decline on a dementia scale that runs from 0 to 18, where higher is worse. After five years, the treated group had worsened 2.05 points less than the comparison group from the United States study, and 2.54 points less than the Swedish group. Within those five years, 61.9 per cent of the treated people moved on to the next stage of the disease, against 77.5 per cent of people in the United States records. Brain swelling, the drug’s main risk, showed up in 13.5 per cent of people in their first year of treatment and in between 0.6 and 3.6 per cent in each later year (the companies’ release).
How sure anyone can be
A comparison with past patients is weaker than a trial with a dummy group. Those patients were not assigned at random alongside the treated ones, so they may differ in ways nobody measured. Also, the 351 people who stayed on the drug for five years may not be typical of everyone who started it. The release gives one limit of its own: check-ups were far apart, and missing scores were filled in using the comparison group’s data. It also notes that the Swedish group started at an earlier stage of the disease. It says that 62 per cent of people with little tau, the second protein of Alzheimer’s disease, had improved after five years, but it does not say how many people that is (the companies’ release). None of this has yet been published in a paper that other scientists have checked.
Four days earlier, on November 13th, 2026, a pen form of the drug that people or their carers can inject at home went on sale in Japan, the second country to have it after the United States. Brain scans are still needed before and during treatment. My estimate for when antibodies like this are in wide use turns on how many people are actually treated, and neither release gives that number, so the estimate is unchanged (the treatment’s page).
The record: An antibody clears amyloid from the brain and slows the decline of Alzheimer's disease · the story entry.
Sources: Eisai and Biogen, "New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension, Presented at CTAD 2026", November 17th, 2026 · Eisai and Biogen, "LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Now Available in Japan for Patients with Early Alzheimer's Disease", November 13th, 2026 · The Clarity AD trial, its entry in the United States trial registry.
Follow the news: the feed · @SentHorizons on X · r/SentientHorizons on Reddit.